Research across Kidney Diseases
Related studies from across the Kidney Diseases family.
26 trials tracked for renal failure: 12 in phase 3 or 4 and 2 with published results. The most-cited published study has 86 citations.
Showing the 26 most-cited and recently-updated of 26 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Management of renal failure involves several pharmacological and procedural interventions. For patients requiring transplant, LCP-Tacro has been evaluated for efficacy; one study reported a low composite endpoint for efficacy failure within 12 months 7. Additionally, switching from Prograf to LCP-Tacro in stable kidney transplant patients was associated with a significant reduction in hand tremors (p=0.0048) 9.
Prograf (tacrolimus) has been studied extensively for transplant outcomes; data showed no statistically significant difference in treatment failures at 12 months (p=0.999) or 24 months (p=0.835) across compared groups 8. Other pharmacological interventions include the use of sodium bicarbonate 12, ferric citrate 5, and Heme Iron Polypeptide (Proferrin), which showed stable hemoglobin concentrations at 6 months 11.
Cardiovascular and metabolic management in renal patients includes the use of 10mg Rosuvastatin 13. For vascular access, the GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface demonstrated significantly higher target lesion primary patency at 6, 12, and 24 months compared to standard alternatives (p=0.008) 10.
Alternative surgical materials such as Human Acellular Vessel (HAV) have been evaluated in phase 3 trials for renal-related applications 4.
AI synthesis of 11 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Kidney Diseases family.